GE's 'Cellular Pharmacogenomics' Deal With TGen Could Promote HCS Use in Personalized Medicine | GenomeWeb

GE Healthcare's recently announced "cellular pharmacogenomics" partnership with the Phoenix, Ariz.-based Translational Genomics Research Institute may show HCS to be a useful tool for genomics-based drug development and eventually, personalized medicine.

The alliance, which is built around GE's IN Cell Analyzer high-content screening platform, is also part of the firm's broader strategy to partner with research institutions that can push its technologies into personalized medicine.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Science this week: convergent evolution in bird hemoglobin, and more.

The Wall Street Journal speaks with patients affected by questionable test results from Theranos.

Researchers link variants in TACR3 to hot flashes during menopause, Live Science reports.

Kuwait says it will alter its law requiring citizens and visitors to provide DNA samples, New Scientist reports.